Prognostic predictive value of total lesion glycolysis from 18F-FDG PET/CT in post-surgical patients with epithelial ovarian cancer

Clinical Nuclear Medicine

Volumn 38, Issue 9, 2013, Pages 715-720

  Liao, Shanshan ^a   Lan, Xiaoli ^a   Cao, Guoxiang ^a   Yuan, Hui ^a   Zhang, Yongxue ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

epithelial ovarian cancer; FDG; PET; prognosis; total lesion glycolysis

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ALGORITHM; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GLYCOLYSIS; HUMAN; LONG TERM CARE; LYMPH NODE METASTASIS; OVARY CARCINOMA; OVARY METASTASIS; OVERALL SURVIVAL; PET SCANNER; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SURGICAL PATIENT; SURVIVAL TIME; TUMOR VOLUME;

EID: 84883448237     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31829f57fa     Document Type: Article

References (31)

1. Kitajima K, Murakami K, Sakamoto S, et al. Present and future of FDG-PET/ CT in ovarian cancer. Ann Nucl Med. 2011;25:155Y164.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277Y300.
3. Fuccio C, Castellucci P, Marzola MC, et al. Noninvasive and invasive staging of ovarian cancer: review of the literature. Clin Nucl Med. 2011;36:889Y893.
4. Schwarz JK, Grigsby PW, Dehdashti F, et al. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med. 2009;50(Suppl 1):64SY73S.
5. Rossing MA, Wicklund KG, Cushing-Haugen KL, et al. Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst. 2010; 102:222Y229.
6. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007;109:221Y227.
7. Son H, Khan SM, Rahaman J, et al. Role of FDG PET/CT in staging of recurrent ovarian cancer. Radiographics. 2011;31:569Y583.
8. Musto A, Rampin L, Nanni C, et al. Present and future of PET and PET/CT in gynaecologic malignancies. Eur J Radiol. 2011;78:12Y20.
9. Castellucci P, Perrone AM, Picchio M, et al. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun. 2007;28:589Y595.
10. Gu P, Pan LL, Wu SQ, et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2009;71:164Y174.
11. Nowosinska E, Avril S, Murray I, et al. FDG-PET/CT as a molecular biomarker in ovarian cancer. Cancer Biomark. 2010;8:167Y175.
12. Yuan Y, Gu ZX, Tao XF, et al. Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/ computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis. Eur J Radiol. 2012;81:1002Y1006.
13. Sebastian S, Lee SI, Horowitz NS, et al. PET-CT vs. CTalone in ovarian cancer recurrence. Abdom Imaging. 2008;33:112Y118.
14. Grassetto G, Groheux D, Marzola MC, et al. FDG PET/CT in ovarian cancer: what about treatment response and prognosis? Clin Nucl Med. 2012;37:54Y56.
15. Lucignani G. SUV and segmentation: pressing challenges in tumour assessment and treatment. Eur J Nucl Med Mol Imaging. 2009;36:715Y720.
16. La TH, Filion EJ, Turnbull BB, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;74:1335Y1341.
17. Hyun SH, Choi JY, Shim YM, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010;17:115Y122.
18. Lee P, Weerasuriya DK, Lavori PW, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69:328Y333.
19. Yan H, Wang R, Zhao F, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy. Acta Radiol. 2011;52:646Y650.
20. Chung HH, Kim JW, Han KH, et al. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol Oncol. 2011;120:270Y274.
21. Chung MK, Jeong HS, Park SG, et al. Metabolic tumor volume of [18F]- fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009;15:5861Y5868.
22. Xie P, Yue JB, Zhao HX, et al. Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2010; 136:883Y889.
23. Liu FY, Chao A, Lai CH, et al. Metabolic tumor volume by 18F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma. Gynecol Oncol. 2012;125:566Y571.
24. Chung HH, Kwon HW, Kang KW, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol. 2012;19:1966Y1972.
25. Roedl JB, Colen RR, Holalkere NS, et al. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol. 2008;89:278Y286.
26. Maffione AM, Ferretti A, Grassetto G, et al. Fifteen different (18)F-FDG PET/ CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging. 2013;40:853Y864.
27. Yu W, Fu XL, Zhang YJ, et al. GTV spatial conformity between different delineation methods by 18FDG PET/CT and pathology in esophageal cancer. Radiother Oncol. 2009;93:441Y446.
28. Chung HH, Kang WJ, Kim JW, et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging. 2007;34:480Y486.
29. Nanni C, Rubello D, Farsad M, et al. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol. 2005;31:792Y797.
30. Nakamura K, Hongo A, Kodama J, et al. The pretreatment of maximum standardized uptake values (SUVmax) of the primary tumor is predictor for poor prognosis for patients with epithelial ovarian cancer. Acta Med Okayama. 2012;66:53Y60.
31. Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994;10:31Y46 pag 721-723